187 related articles for article (PubMed ID: 28681680)
1. Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.
Bhat VS; Meek MEB; Valcke M; English C; Boobis A; Brown R
Crit Rev Toxicol; 2017 Oct; 47(9):729-749. PubMed ID: 28681680
[TBL] [Abstract][Full Text] [Related]
2. Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ingredients: Investigation of recent drug datasets.
Poulin P; Arnett R
Regul Toxicol Pharmacol; 2017 Dec; 91():142-150. PubMed ID: 29107009
[TBL] [Abstract][Full Text] [Related]
3. Practical application of kinetic data in risk assessment--an IPCS initiative.
Meek B; Renwick A; Sonich-Mullin C;
Toxicol Lett; 2003 Feb; 138(1-2):151-60. PubMed ID: 12559699
[TBL] [Abstract][Full Text] [Related]
4. Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment.
Meek ME; Barton HA; Bessems JG; Lipscomb JC; Krishnan K
Regul Toxicol Pharmacol; 2013 Jun; 66(1):116-29. PubMed ID: 23535119
[TBL] [Abstract][Full Text] [Related]
5. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans.
Dorne JL; Renwick AG
Toxicol Sci; 2005 Jul; 86(1):20-6. PubMed ID: 15800035
[TBL] [Abstract][Full Text] [Related]
6. The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective.
Gundert-Remy U; Sonich-Mullin C;
Sci Total Environ; 2002 Apr; 288(1-2):3-11. PubMed ID: 12013545
[TBL] [Abstract][Full Text] [Related]
7. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
Reichard JF; Maier MA; Naumann BD; Pecquet AM; Pfister T; Sandhu R; Sargent EV; Streeter AJ; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S67-78. PubMed ID: 27224509
[TBL] [Abstract][Full Text] [Related]
8. An approach for integrating toxicogenomic data in risk assessment: the dibutyl phthalate case study.
Euling SY; Thompson CM; Chiu WA; Benson R
Toxicol Appl Pharmacol; 2013 Sep; 271(3):324-35. PubMed ID: 23537663
[TBL] [Abstract][Full Text] [Related]
9. Advancing human health risk assessment: integrating recent advisory committee recommendations.
Dourson M; Becker RA; Haber LT; Pottenger LH; Bredfeldt T; Fenner-Crisp PA
Crit Rev Toxicol; 2013 Jul; 43(6):467-92. PubMed ID: 23844697
[TBL] [Abstract][Full Text] [Related]
10. Derivation of a chemical-specific adjustment factor (CSAF) for use in the assessment of risk from chronic exposure to ethylene glycol: application of International Programme for Chemical Safety guidelines.
Palmer RB; Brent J
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):576-84. PubMed ID: 15990139
[TBL] [Abstract][Full Text] [Related]
11. Developmental toxicity risk assessment: consensus building, hypothesis formulation, and focused research.
Kimmel CA
Drug Metab Rev; 1996; 28(1-2):85-103. PubMed ID: 8744591
[TBL] [Abstract][Full Text] [Related]
12. Data derived Extrapolation Factors for developmental toxicity: A preliminary research case study with perfluorooctanoate (PFOA).
Dourson ML; Gadagbui B; Onyema C; McGinnis PM; York RG
Regul Toxicol Pharmacol; 2019 Nov; 108():104446. PubMed ID: 31425727
[TBL] [Abstract][Full Text] [Related]
13. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants.
Valcke M; Krishnan K
J Appl Toxicol; 2014 Mar; 34(3):227-40. PubMed ID: 24038072
[TBL] [Abstract][Full Text] [Related]
15. Determination of a site-specific reference dose for methylmercury for fish-eating populations.
Shipp AM; Gentry PR; Lawrence G; Van Landingham C; Covington T; Clewell HJ; Gribben K; Crump K
Toxicol Ind Health; 2000 Nov; 16(9-10):335-438. PubMed ID: 11762928
[TBL] [Abstract][Full Text] [Related]
16. A chemical-specific adjustment factor for human interindividual differences in kinetics for glutamates (E620-625).
Rietjens IM; Tanaka T; Masuzawa Y; Nakamura H; Ishizaka Y; Teoh KN
Food Chem Toxicol; 2021 Jan; 147():111910. PubMed ID: 33309877
[TBL] [Abstract][Full Text] [Related]
17. Metabolism, variability and risk assessment.
Dorne JL
Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
[TBL] [Abstract][Full Text] [Related]
18. Data derived extrapolation factors (DDEFs) for rat to human interspecies extrapolation for the HPPD inhibitor mesotrione.
Pecquet AM; Bridgwood K; Cowie D; Hofstra A; Wu Y; Whalley S; Webb SD
Crit Rev Toxicol; 2024 Jun; ():1-12. PubMed ID: 38869005
[TBL] [Abstract][Full Text] [Related]
19. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts.
Zu K; Pizzurro DM; Lewandowski TA; Goodman JE
Regul Toxicol Pharmacol; 2017 Oct; 89():83-94. PubMed ID: 28720346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
